TCA
TEVA icon

Transcend Capital Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Transcend Capital Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$417K Buy
12,319
+35
+0.3% +$1.17K 0.03% 519
2026
Q1 		$370K Buy
12,284
+16
+0.1% +$515 0.03% 478
2025
Q4 		$383K Sell
12,268
-347
-3% -$8.55K 0.03% 435
2025
Q3 		$255K Sell
12,615
-1,077
-8% -$18.9K 0.02% 594
2025
Q2 		$229K Buy
13,692
+973
+8% +$15.7K 0.02% 543
2025
Q1 		$195K Sell
12,719
-35
-0.3% -$625 0.01% 576
2024
Q4 		$281K Buy
12,754
+32
+0.3% +$582 0.02% 457
2024
Q3 		$229K Buy
12,722
+76
+0.6% +$1.33K 0.02% 545
2024
Q2 		$205K Buy
12,646
+196
+2% +$3.02K 0.01% 556
2024
Q1 		$176K Sell
12,450
-93
-0.7% -$1.17K 0.01% 507
2023
Q4 		$131K Buy
12,543
+1,500
+14% +$14K 0.01% 487
2023
Q3 		$113K Hold
11,043
– – 0.01% 472
2023
Q2 		$83.2K Hold
11,043
– – 0.01% 478
2023
Q1 		$97.7K Sell
11,043
-1,900
-15% -$18.8K 0.01% 468
2022
Q4 		$118K Buy
12,943
+93
+0.7% +$811 0.01% 474
2022
Q3 		$104K Hold
12,850
– – 0.01% 466
2022
Q2 		$97K Hold
12,850
– – 0.01% 481
2022
Q1 		$121K Buy
12,850
+1,900
+17% +$15.9K 0.01% 497
2021
Q4 		$88K Sell
10,950
-150
-1% -$1.35K 0.01% 476
2021
Q3 		$104K Sell
11,100
-547
-5% -$5.12K 0.01% 477
2021
Q2 		$114K Buy
11,647
+547
+5% +$5.79K 0.02% 318
2021
Q1 		$128K Hold
11,100
– – 0.02% 402
2020
Q4 		$107K Hold
11,100
– – 0.01% 368
2020
Q3 		$100K Buy
+11,100
New +$117K 0.02% 255
2020
Q2 		– Sell
-10,950
Closed -$98K – 190
2020
Q1 		$98K Buy
+10,950
New +$112K 0.03% 204

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Transcend Capital Advisors's TEVA Position: Q2 2026 in Review

Transcend Capital Advisors increased its Teva Pharmaceuticals (TEVA) stake by 0.28% in Q2 2026, buying an estimated $1.17K and bringing the position to 12,319 shares worth $417K. The position accounts for 0.03% of the portfolio, ranked #519.

Transcend Capital Advisors first reported a position in TEVA in Q1 2020 and has held it in 25 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Transcend Capital Advisors held 12,319 shares of Teva Pharmaceuticals worth $417K as of Q2 2026.
  • Transcend Capital Advisors bought 35 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.17K.
  • Teva Pharmaceuticals made up 0.03% of Transcend Capital Advisors's portfolio in Q2 2026, its #519 holding.
  • Transcend Capital Advisors first reported a position in Teva Pharmaceuticals in Q1 2020 and has held it in 25 quarters since.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Transcend Capital Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.